Cyproheptadine treatment in neuroleptic-induced akathisia.
Level II
Where this comes from
- Record sourced from PubMed, PMID 8829717.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cyproheptadine, an antiserotonergic agent, was used to treat neuroleptic-induced akathisia. In an open clinical trial 17 neuroleptic-treated patients with akathisia were administered cyproheptadine (16 mg/day) over 4 days. Assessment of akathisia, psychosis and depression were monitored by BAS, BPRS and HAM-D. All subjects showed improvement in the severity of akathisia, which in the majority (15/17) was of a marked degree. There was no aggravation of psychosis or depression. Symptoms of akathisia returned when cyproheptadine was discontinued. Cyproheptadine may be useful in neuroleptic-induced akathisia.
Medical subject headings
- Akathisia, Drug-Induced
- Antipsychotic Agents
- Cyproheptadine
- Psychotic Disorders
- Schizophrenia
- Serotonin Antagonists